Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis
Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis
复制标题
DOI：
10.1016/j.jpba.2021.113971
复制
发表时间：
2021-02-24
影响因子：
3.4
通讯作者：
Szuba, Andrzej
中科院分区：
文献类型：
--
作者：
Dudka, Ilona;Chachaj, Angelika;Szuba, Andrzej
在这项初步研究中，我们对开始使用生物疾病缓解抗风湿药物（bDMARDs）治疗的类风湿关节炎（RA）患者进行了代谢分析。该研究的主要目的是评估与治疗成功和所涉及的代谢途径相关的代谢变化。通过1H-1 NMR，液相色谱-质谱，和气相色谱-质谱法，并通过统计学和多变量分析进行评估。在应答者组中，与治疗前的概况相比，在bDMARD治疗三个月后观察到他们的代谢模式的显著差异。我们确定了24种代谢物，这些代谢物在这两个时间点之间存在显著差异，主要属于氨基酸代谢、肽、脂质、辅因子、维生素和外源性物质。11种代谢物在治疗前区分了应答者与非应答者。此外，N-乙酰葡萄糖胺和N-乙酰半乳糖胺（GlycA）和N-乙酰神经氨酸（GlycB）在治疗三个月后的反应者与无反应者的比较中持续存在显著性。受试者工作特征（ROC）曲线分析结果表明，这两种代谢产物可预测RA患者对bDMARD的反应潜力，为研究RA患者对bDMARD的反应和治疗效果提供了新的思路。GlycA和GlycB是在bDMARD治疗开始前识别应答患者的有前景的生物标志物。(C)2021爱思唯尔有限公司版权所有。
In this pilot study, we carried out metabolic profiling of patients with rheumatoid arthritis (RA) starting therapy with biological disease-modifying antirheumatic drugs (bDMARDs). The main aim of the study was to assess the occurring metabolic changes associated with therapy success and metabolic pathways involved. In particular, the potential of the metabolomics profiles was evaluated as therapeutically valuable prognostic indicators of the effectiveness of bDMARD treatment to identify responders versus non-responders prior to implementing treatment.Plasma metabolomic profiles of twenty-five patients with RA prior bDMARD treatment and after three months of therapy were obtained by H-1 NMR, liquid chromatography - mass spectrometry, and gas chromatography - mass spectrometry and evaluated by statistical and multivariate analyses.In the group of responders, significant differences in their metabolic patterns were seen after three months of the bDMARD therapy compared with profiles prior to treatment. We identified 24 metabolites that differed significantly between these two-time points mainly belonging to amino acid metabolism, peptides, lipids, cofactors, and vitamins and xenobiotics. Eleven metabolites differentiated responders versus non-responders before treatment. Additionally, N-acetylglucosamine and N-acetylgalactosamine (GlycA) and N-acetylneuraminic acid (GlycB) persisted significant in comparison responders to nonresponders after three months of therapy. Moreover, those two metabolites indicated prediction of response potential by results of receiver-operating characteristic (ROC) curve analysis.The applied analysis provides novel insights into the metabolic pathways involved in RA patient's response to bDMARD and therapy effectiveness. GlycA and GlycB are promising biomarkers to identify responding patients prior onset of bDMARD therapy. (C) 2021 Elsevier B.V. All rights reserved.